Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials

By sjmartinez • February 11, 2023

Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023 Feb 10;188(2):198-207. doi: 10.1093/bjd/ljac040. PMID: 36763857.

Tags: Dermatology, Publications

GLP-1RAs and cardiovascular risk reduction in psoriasis: A retrospective cohort study

Ma EJ, Roberts AM, Jeong CY, Chou P, Katz A, Nong Y, Johnsen N, Yan M, Ochoa MT, Armstrong AW. GLP-1RAs and cardiovascular risk reduction[...]

Ethical considerations regarding environmental impact of generative artificial intelligence (AI) in dermatology

Ebriani J, Yan MJ, Lester J, Farshchian M, Wongvibulsin S. Ethical considerations regarding environmental impact of generative artificial intelligence (AI) in dermatology. J Am Acad[...]

Autoimmune Bullous Diseases: Therapeutic Update

Kasperkiewicz M, van Beek N, Schmidt E. Autoimmune Bullous Diseases: Therapeutic Update. Drugs. 2026 Feb 23. doi: 10.1007/s40265-026-02292-3. Epub ahead of print. PMID: 41729378.